|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2008-7-8
|
|
pubmed:abstractText |
The primary objectives of phase-I trials include the definition of drug toxicities and the recommendation of phase-II doses. In order to safeguard the well-being of its participants, a common inclusion criterion is that of life expectancy >3 months. However, previous studies have shown that about 20% of these patients do not survive beyond this time-point.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jul
|
|
pubmed:issn |
0959-8049
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
44
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1536-40
|
|
pubmed:meshHeading |
pubmed-meshheading:18550361-Adolescent,
pubmed-meshheading:18550361-Adult,
pubmed-meshheading:18550361-Aged,
pubmed-meshheading:18550361-Aged, 80 and over,
pubmed-meshheading:18550361-Case-Control Studies,
pubmed-meshheading:18550361-Clinical Trials, Phase I as Topic,
pubmed-meshheading:18550361-Cohort Studies,
pubmed-meshheading:18550361-Female,
pubmed-meshheading:18550361-Humans,
pubmed-meshheading:18550361-Male,
pubmed-meshheading:18550361-Middle Aged,
pubmed-meshheading:18550361-Neoplasms,
pubmed-meshheading:18550361-Patient Selection,
pubmed-meshheading:18550361-Prognosis,
pubmed-meshheading:18550361-Retrospective Studies,
pubmed-meshheading:18550361-Risk Factors,
pubmed-meshheading:18550361-Survival Analysis
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
90-Days mortality rate in patients treated within the context of a phase-I trial: how should we identify patients who should not go on trial?
|
|
pubmed:affiliation |
Drug Development Unit, Royal Marsden Hospital and Institute of Cancer Research, Downs Road, SM2 5PT Sutton, United Kingdom. hendrik-tobias.arkenau@icr.ac.uk
|
|
pubmed:publicationType |
Journal Article,
Comparative Study
|
